Affiliate Disclosure
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →
Educational Notice
This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on biotinoyl tripeptide-1. It is not medical advice, a treatment recommendation, or a substitute for professional consultation. Hair loss has multiple causes requiring individual assessment. Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
A Comprehensive Evidence Review — Follicle Anchoring, ECM Biology, and the Procapil® Clinical Data
Biotinoyl tripeptide-1 targets a mechanism of hair loss that rarely gets discussed in the consumer-facing world but is well-characterized in follicle biology: the progressive detachment of hair follicles from the extracellular matrix scaffolding that holds them in the dermis. In androgenetic alopecia and other progressive hair loss conditions, DHT-mediated changes don’t only suppress Wnt signaling — they also downregulate the adhesion molecules and basement membrane proteins that anchor the follicle’s bulge region to the surrounding dermis. A follicle that is losing its ECM anchorage is a follicle that is easier to shed, harder to regrow, and progressively more vulnerable to the miniaturization cycle. Biotinoyl tripeptide-1 works by upregulating laminin-5 and collagen IV — the two principal basement membrane components that form the follicle’s structural anchor to the dermis.
The compound is better known in its commercial formulation context than as a standalone ingredient. It is one of three components in Procapil® — a Sederma/Croda-developed hair care active that combines biotinoyl tripeptide-1 with apigenin (a flavonoid that inhibits 5α-reductase) and oleanolic acid (a DHT-suppressing triterpene). The published clinical evidence for hair improvement is attached to the Procapil® combination rather than biotinoyl tripeptide-1 in isolation, which creates the same attribution challenge encountered with combination ingredients throughout Cluster G. Understanding what biotinoyl tripeptide-1 contributes specifically — versus what the apigenin or oleanolic acid components contribute — requires separating the ingredient’s own documented biology from the combination’s clinical outcomes.
This article examines the ECM anchoring mechanism, what the evidence shows for the combination and the ingredient independently, and how this specific approach to follicle preservation fits into the broader hair loss intervention landscape.
Quick Facts
INCI Name
Biotinoyl Tripeptide-1
Mechanism Class
ECM signal peptide — upregulates laminin-5 and collagen IV to reinforce follicle basement membrane anchorage
Evidence Tier
Pilot Data — combination study (Procapil®) with human outcomes
Commercial Context
Key peptide component of Procapil® (Sederma/Croda) — also combined with apigenin and oleanolic acid
Structure
Biotin conjugated to a GHK-sequence tripeptide (Gly-His-Lys) — delivers biotin alongside the matrikine signal
Regulatory Status
Cosmetic ingredient. Not FDA approved as a drug.
WADA Status
Not prohibited
Key Comparator
Acetyl tetrapeptide-3 — related ECM-anchoring approach; both included in published Capixyl® comparison data
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Biotinoyl Tripeptide-1?
Biotinoyl tripeptide-1 is a synthetic peptide consisting of a biotin molecule covalently conjugated to a Gly-His-Lys (GHK) tripeptide sequence. The GHK sequence — the same core sequence found in GHK-Cu and palmitoyl tripeptide-1 — is a collagen-derived matrikine that activates fibroblast and follicle dermal papilla cell signaling through growth factor and ECM regulation pathways. The biotin conjugation serves two purposes: it provides biotin (vitamin B7) as a functional cofactor for keratin synthesis, and it creates a lipophilic handle that improves the peptide’s affinity for the stratum corneum and dermal delivery.
In the follicle context, biotinoyl tripeptide-1’s primary documented activity is upregulation of laminin-5 (laminin-332) and collagen IV — the principal structural proteins of the follicular basement membrane. Laminin-5 is an anchoring laminin that connects the follicle outer root sheath cells to the basement membrane through β4 integrin binding; collagen IV provides the structural scaffold of the basement membrane itself. Together they form the adhesion system that keeps the follicle rooted in the dermis. In progressive hair loss, this adhesion system is compromised, making follicles more susceptible to premature shedding and contributing to the shortening of the anagen phase.
The biotin component is relevant beyond its conjugation role. Biotin deficiency produces hair loss and nail fragility — biotin is essential for carboxylase enzymes involved in fatty acid synthesis and amino acid metabolism, including pathways relevant to keratin protein production. Biotinoyl tripeptide-1 thus delivers both a signaling peptide and a keratin synthesis cofactor in a single molecule, though the clinical relevance of the biotin delivery component specifically in individuals without biotin deficiency is uncertain.
Origins and Development
Biotinoyl tripeptide-1 was developed by Sederma (now part of Croda International), the same French cosmetic ingredient company that developed Matrixyl (palmitoyl pentapeptide-4). Its development followed Sederma’s recognition that follicle ECM anchoring was an underaddressed mechanism in cosmetic hair care — the existing market was dominated by DHT inhibitors (finasteride, saw palmetto), vasodilators (minoxidil), and scalp-conditioning approaches, with relatively little targeting of the structural biology of follicle retention.
Sederma developed biotinoyl tripeptide-1 as the peptide component of the Procapil® complex, a three-ingredient commercial active combining the peptide with apigenin (a plant-derived 5α-reductase inhibitor from chamomile) and oleanolic acid (a triterpene with anti-androgenic activity from olive and rosemary). The rationale for the combination was multi-mechanism: address DHT-mediated signaling (apigenin, oleanolic acid) while simultaneously reinforcing the ECM anchorage that progressive miniaturization erodes (biotinoyl tripeptide-1). Published studies for Procapil® were sponsored by Sederma and represent the primary human clinical evidence base for biotinoyl tripeptide-1.
Follicle ECM Biology: The Anchoring Problem
Each hair follicle is an epithelial invagination embedded in the dermis — a tube of specialized cells extending from the epidermis downward to the dermal papilla at the follicle base. The structural integrity of this invagination depends on the follicular basement membrane: a specialized ECM layer that surrounds the outer root sheath, separating it from the surrounding dermis and providing adhesion substrates for follicle cell survival and cycling.
The basement membrane is composed primarily of collagen IV (which forms a structural meshwork), laminin-332/laminin-5 (which mediates adhesion through β4 integrin and α6 integrin receptors on outer root sheath cells), nidogen, and perlecan. Laminin-332 is particularly critical — it is the primary ligand for hemidesmosomes, the cell-to-basement-membrane adhesion structures that anchor follicle keratinocytes. When laminin-332 expression is reduced or basement membrane continuity is disrupted, follicle cells lose hemidesmosomal attachment, outer root sheath integrity is compromised, and the follicle becomes susceptible to premature entry into catagen and accelerated shedding.
In androgenetic alopecia, DHT-mediated signaling in dermal papilla cells produces downstream effects that include reduced laminin-332 expression and basement membrane thinning in miniaturized follicles. This ECM deterioration is not the primary driver of AGA — that is the Wnt/CXXC5 axis and the dermal papilla cell signaling changes mediated by androgen receptors — but it is a contributing factor that compounds over time. A follicle losing both its Wnt-driven growth signal and its structural ECM anchor is doubly vulnerable to miniaturization and eventual follicle loss.
Plain English
Each hair follicle is anchored in the skin like a post set in concrete. In pattern hair loss, that concrete gradually degrades — the structural proteins holding the follicle in place get weaker. Biotinoyl tripeptide-1 targets those structural proteins specifically, trying to reinforce the anchor rather than addressing the hormonal signals that are weakening it. Most other hair loss treatments address the hormonal and signaling problems; this approach addresses the structural deterioration.
Mechanism of Action
Biotinoyl tripeptide-1 activates follicle dermal papilla cells and outer root sheath keratinocytes through the GHK peptide sequence’s interaction with growth factor receptors and ECM-signaling pathways. The primary documented cellular response is upregulation of laminin-5 (LAMA3, LAMB3, LAMC2 gene expression) and collagen IV (COL4A1, COL4A2) — the basement membrane components that provide follicle anchorage. This upregulation is documented in in vitro human follicle cell culture studies included in Sederma’s technical documentation for Procapil®.
The biotin component contributes through its role as a cofactor for carboxylase enzymes involved in fatty acid synthesis and amino acid catabolism. In follicle keratinocytes, these pathways support the high-rate protein synthesis required for hair shaft production. Biotin’s direct effect on keratin gene expression is debated — the clinical benefit of supplemental biotin for hair is primarily observed in individuals with documented biotin deficiency, and the baseline benefit in biotin-replete individuals is less established. Whether the biotin conjugation in biotinoyl tripeptide-1 provides meaningful additional benefit beyond the GHK peptide component alone has not been directly tested.
Plain English
Biotinoyl tripeptide-1 tells follicle cells to produce more of the structural proteins that hold the follicle in place. In a cell culture dish, this happens reliably. Whether enough of the compound reaches follicle cells after topical application through the scalp to produce the same effect in living skin is the question the in vitro data alone cannot answer.
Procapil®: Understanding the Combination Context
Procapil® is a three-ingredient commercial active developed and marketed by Sederma (Croda). Its components are biotinoyl tripeptide-1 (the ECM-anchoring peptide), apigenin (a flavonoid from chamomile with published 5α-reductase inhibitory activity), and oleanolic acid (a triterpene from olive and rosemary with anti-androgenic properties). All three components address different aspects of AGA pathophysiology — the combination was designed to cover DHT reduction and ECM preservation simultaneously.
The primary human clinical evidence for Procapil® is a Sederma-sponsored study in which Procapil® at 3% was applied to the scalps of men with AGA for 4 months. The study reported a statistically significant reduction in hair loss (measured by hair pull test and hair count in a defined scalp zone) and improvement in hair density compared to baseline. A separate publication reported similar improvements over a 4-month period in a cohort with both male and female pattern hair loss.
Evidence context: All published Procapil® human data is industry-sponsored by Sederma. The studies are small, typically without a placebo-controlled group or with limited control methodology. Biotinoyl tripeptide-1’s individual contribution to the combination’s effects — separate from apigenin’s 5α-reductase inhibition or oleanolic acid’s anti-androgenic activity — cannot be isolated from combination study data. This is the same attribution challenge as Matrixyl 3000 and the Cluster G combination peptides.
Key Research and Studies
In Vitro ECM Studies
Sederma’s technical documentation includes in vitro studies showing biotinoyl tripeptide-1 upregulates laminin-5 and collagen IV gene expression in human follicle outer root sheath cells and dermal papilla cells. These studies use quantitative PCR and protein-level measurements to confirm the ECM anchoring mechanism at the cellular level. The concentration ranges used in these studies are relevant to typical topical formulation concentrations, providing a reasonable basis for the mechanism claim. They do not address transcutaneous delivery or in vivo follicle tissue concentrations.
Procapil® Human Clinical Studies
The primary published Procapil® clinical study enrolled 35 volunteers with AGA and applied 3% Procapil® solution twice daily for 4 months. Outcomes measured by phototrichogram showed a 46% reduction in hair loss rate compared to baseline and a 9% increase in anagen hair count. A second manufacturer study in a broader population reported reduction in hair loss symptoms and patient self-assessment improvements. Both studies are industry-sponsored, small, and not independently replicated. No head-to-head comparison with minoxidil or finasteride has been published for Procapil®.
Independent Research on ECM Anchoring in AGA
Independent academic research has confirmed that laminin-332 expression is reduced in miniaturized follicles from AGA scalps compared to non-balding scalps, and that basement membrane integrity is compromised in follicles undergoing progressive miniaturization. This independent research on AGA pathology validates the biological rationale for targeting ECM anchoring — the problem biotinoyl tripeptide-1 is designed to address is genuinely present in AGA. This is a meaningful distinction from compounds whose target tissues are not independently validated as impaired in the condition being treated.
Common Claims versus Current Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Reduces hair loss by 46%” | This figure comes from the Sederma Procapil® study (46% reduction vs. baseline, not vs. placebo). Measured by phototrichogram in 35 participants. Industry-sponsored. The figure is real from the study; its clinical significance depends on methodology not available in public documents. | Combination study result — biotinoyl contribution unquantified |
| “Strengthens hair roots” | Mechanistically grounded — upregulation of laminin-5 and collagen IV directly addresses the structural anchorage system. In vitro data supports the mechanism. Clinical translation to “stronger roots” in humans is not directly measured in published studies. | Mechanism well-supported; clinical translation not directly measured |
| “As effective as minoxidil” | No head-to-head comparison published. Cannot be supported or refuted from available evidence. | No comparative evidence — claim unsupported |
| “Works for all types of hair loss” | Evidence is in AGA only. ECM anchoring is specifically impaired in AGA; its relevance to alopecia areata, telogen effluvium, or traction alopecia is mechanistically distinct. | AGA evidence only — other types unstudied |
| “Biotin for hair growth” | Biotin deficiency causes hair loss and supplementation reverses it in deficient individuals. Supplemental biotin in biotin-replete individuals does not have established hair growth benefits in published evidence. The biotin in biotinoyl tripeptide-1 is delivered locally to the scalp — whether this produces meaningful local biotin delivery advantage is unstudied. | Relevant only in deficiency — marginal evidence for replete individuals |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
The Human Evidence Landscape
Biotinoyl tripeptide-1’s human evidence sits in the combination-only category — all published clinical outcomes are for the Procapil® three-ingredient complex, and the peptide’s individual contribution cannot be isolated. This is a weaker evidence position than PTD-DBM, which has at least a standalone active tested in a published RCT. It is a stronger position than purely preclinical compounds, because the combination’s human use data provides some evidence that the overall approach produces measurable hair outcomes in real humans.
The biological plausibility is high — laminin-332 deficiency in AGA follicles is independently documented, and the in vitro evidence for biotinoyl tripeptide-1’s ECM upregulation is internally consistent. The gap between strong in vitro mechanism and limited clinical attribution is the central honest assessment: this compound has a good reason to work and human combination data showing something works, but we don’t know how much biotinoyl tripeptide-1 specifically contributes to that outcome.
Safety, Risks, and Limitations
Biotinoyl tripeptide-1 has an excellent safety profile. The GHK tripeptide sequence is endogenous — it is a fragment of the C-terminal region of the α2 chain of type I collagen and is processed normally by human physiology. Biotin is a water-soluble vitamin with no established toxicity at oral supplementation levels orders of magnitude above dietary requirements. Contact sensitization to biotinoyl tripeptide-1 is not a reported concern. No systemic adverse events have been attributed to topical biotinoyl tripeptide-1 in published cosmetic or clinical use. The safety profile is favorable across all application routes at the concentrations relevant to cosmetic and research use.
For scalp microneedling with biotinoyl tripeptide-1 solution, the same sterility considerations apply as for all scalp microneedling — cosmetic-grade materials are not manufactured to pharmaceutical sterility standards, and the scalp’s proximity to the highly vascular dermis (and therefore to systemic circulation) means that contaminated materials introduced through open channels pose a real infection risk. Use bacteriostatic water for injection as the reconstitution medium for any peptide intended for scalp microneedling.
Legal and Regulatory Status
Biotinoyl tripeptide-1 is a cosmetic ingredient regulated under standard cosmetic frameworks in the US (not FDA pre-market approved) and the EU. Procapil® is a registered tradename of Croda/Sederma; generic biotinoyl tripeptide-1 is available from multiple cosmetic ingredient suppliers. WADA: not prohibited.
Research Protocols and Formulation Considerations
Concentration: The Procapil® combination study used 3% of the three-ingredient complex. Biotinoyl tripeptide-1 concentration within that complex is not publicly specified by Sederma. Supplier recommendations for standalone biotinoyl tripeptide-1 typically suggest 1–4% in finished formulations.
Application: Leave-on scalp solution applied twice daily. Scalp massage for 1–2 minutes post-application improves distribution and may enhance follicle penetration. Do not rinse — contact time is critical for transcutaneous delivery.
Combination strategy: Biotinoyl tripeptide-1 targets ECM anchoring, which is mechanistically distinct from and non-competing with Wnt activation (PTD-DBM), DHT suppression (finasteride, apigenin), or vasodilation (minoxidil). A stack combining PTD-DBM (Wnt/growth signal), biotinoyl tripeptide-1 (ECM anchoring), and minoxidil (follicle perfusion) covers three independent mechanisms with no molecular overlap. The Procapil® formulation itself combines biotinoyl tripeptide-1 with DHT-addressing ingredients — formulators using standalone biotinoyl tripeptide-1 can add their own DHT-addressing actives alongside it.
Dosing and Delivery: What the Research Shows
Topical Application
Twice-daily leave-on aqueous or light serum formulation applied to affected scalp areas. The evidence anchor is the Procapil® combination study at 3% total complex, twice daily for 4 months. Biotin conjugation improves stratum corneum affinity relative to unconjugated GHK peptide, providing some delivery advantage — though reaching follicle outer root sheath cells at the depth of the follicle remains a challenge for topical delivery. Scalp skin is thicker than facial skin in some areas and has a different appendageal (follicle and sebaceous gland) density than face or arm, which creates a different transdermal delivery profile. The peripilar pathway — absorption through the follicle channel itself — may be a relevant route for scalp-applied compounds.
Scalp Microneedling / Stamping
Scalp microneedling (0.5–1.0 mm stamp) followed immediately by biotinoyl tripeptide-1 solution application is widely practiced in the hair loss self-experimentation community. The ECM-anchoring target cells (outer root sheath cells, follicle keratinocytes) are at dermal depth directly accessible via microneedling channels at 0.5–1.0 mm. This is a better mechanistic match between needle depth and target cell location than for NMJ-targeting facial peptides. No published trial has studied this specific combination, but the biology is coherent and the scalp microneedling + topical combination evidence (primarily with minoxidil) supports the general approach. Sterility requirements: bacteriostatic water for injection for reconstitution; clean device and skin preparation.
Scalp Mesotherapy (Professional)
Professional intradermal scalp injection delivers biotinoyl tripeptide-1 directly to the dermal layer at follicle proximity — bypassing all barrier limitations and placing the compound within diffusion distance of follicle outer root sheath cells. This route has the strongest mechanistic rationale for achieving effective concentrations at the ECM target. No published trial of mesotherapy-delivered biotinoyl tripeptide-1 has been identified. As with all scalp mesotherapy, professional administration with pharmaceutical-grade or at minimum sterile-prepared materials is the appropriate standard.
Delivery Routes in Self-Experimentation Communities
| Route | Community Use | Evidence | Key Risks |
|---|---|---|---|
| Topical serum / Procapil® product | Common — both as commercial Procapil® products and standalone biotinoyl tripeptide-1 in DIY serums | Combination (Procapil®) human pilot data; in vitro ECM mechanism; independent AGA laminin-332 deficit data | Low — excellent safety profile; source quality varies |
| Scalp microneedling + topical | Widely practiced — among the most common hair loss self-experimentation protocols alongside PTD-DBM and minoxidil | No specific trial; mechanistically coherent — target cell depth matches microneedling range well | Moderate — scalp sterility; bacteriostatic water required; temporary post-procedure shedding is normal |
| Scalp mesotherapy (professional) | Medical procedure context; not at-home | Established procedure for hair loss; biotinoyl-specific trial absent; strong delivery rationale | Low in professional context with proper sterile technique |
Biotinoyl tripeptide-1 / Procapil® has solid recognition in the hair loss research community — the ECM anchoring mechanism resonates with more biologically sophisticated users, and the Procapil® combination has enough published documentation to give it credibility above the purely anecdotal tier. The most common sophisticated protocol combines PTD-DBM (Wnt activation) + biotinoyl tripeptide-1 (ECM anchoring) + minoxidil (perfusion) — covering independent mechanisms across the follicle biology landscape.
Frequently Asked Questions
Q: What is biotinoyl tripeptide-1 and how does it address hair loss?
A: Biotinoyl tripeptide-1 is a synthetic peptide consisting of biotin conjugated to the GHK tripeptide sequence (Gly-His-Lys). It works by upregulating laminin-5 and collagen IV — the structural proteins that form the follicle’s basement membrane and anchor it to the dermis. In androgenetic alopecia, these anchoring proteins are progressively reduced in miniaturizing follicles, making them easier to shed and harder to maintain in the growth phase. Most hair loss treatments address hormonal signaling (finasteride, DHT) or follicle perfusion (minoxidil) — biotinoyl tripeptide-1 specifically addresses the structural deterioration of the follicle anchor itself.
Q: What is Procapil® and does it work?
A: Procapil® is a three-ingredient complex developed by Sederma (Croda) combining biotinoyl tripeptide-1 (ECM anchoring), apigenin (a plant-derived 5α-reductase inhibitor), and oleanolic acid (anti-androgenic triterpene). Sederma-sponsored studies show approximately 46% reduction in hair loss rate and improved anagen counts at 4 months in small cohorts. The evidence is real but comes with limitations: industry-sponsored, small sample sizes, no placebo arm in the primary publication, and no head-to-head comparison with minoxidil. Whether biotinoyl tripeptide-1 specifically drives those results — versus the apigenin or oleanolic acid — cannot be determined from combination study data alone.
Q: How does biotinoyl tripeptide-1 compare to acetyl tetrapeptide-3?
A: Both are ECM-anchoring hair peptides targeting follicle basement membrane reinforcement, but via different sequences and in different commercial contexts (Procapil® vs. Capixyl®). Biotinoyl tripeptide-1 uses the GHK sequence with a biotin conjugation and emphasizes laminin-5 upregulation. Acetyl tetrapeptide-3 uses an acetylated sequence with a red clover extract partner and emphasizes laminin-5 alongside additional ECM proteins. Both have small industry-sponsored combination human studies. A detailed comparison of the two compounds is available in the Acetyl Tetrapeptide-3 article and the Copper Peptides for Hair comparison. For most self-experimenters using both makes more sense than choosing between them — they’re inexpensive enough that the marginal cost of including both is low.
Q: Can biotinoyl tripeptide-1 be used with scalp microneedling?
A: Yes, and the mechanistic fit is good. The follicle outer root sheath cells that produce laminin-5 and collagen IV in response to biotinoyl tripeptide-1 are located in the dermis at depths accessible to 0.5–1.0 mm microneedling channels. This is a better target-depth match than NMJ-targeting facial peptides whose targets are below practical needle depth. No published trial exists for this specific combination. Use bacteriostatic water for injection as the reconstitution medium — not commercial serums or regular water — since microneedling bypasses the stratum corneum barrier and cosmetic-grade materials are not manufactured to pharmaceutical sterility standards.
Q: Does the biotin in biotinoyl tripeptide-1 help with hair growth?
A: Biotin is essential for keratin synthesis and biotin deficiency causes hair loss — supplementation reverses hair loss in deficient individuals. However, supplemental biotin in biotin-replete individuals (which describes most people eating a normal diet) has not been shown to produce meaningful hair growth benefits in published clinical evidence. The biotin in biotinoyl tripeptide-1 is delivered topically to the scalp — whether this creates a meaningful local biotin advantage or simply adds to the peptide’s stratum corneum affinity is not directly established. The GHK peptide component’s ECM signaling activity is the better-characterized mechanism.
Q: How does biotinoyl tripeptide-1 fit with PTD-DBM and minoxidil?
A: The three compounds target completely different and non-competing aspects of follicle biology: PTD-DBM reactivates Wnt/β-catenin signaling to promote anagen entry (the growth signal), biotinoyl tripeptide-1 reinforces the ECM structural anchorage (the structural integrity), and minoxidil improves follicle perfusion and extends anagen duration (the vasodilation/channel mechanism). No molecular overlap, no competition for the same binding site, three different problems addressed simultaneously. No published trial has studied this combination, but the pharmacological logic for combining them is as strong as any multi-mechanism stack in the hair loss category.
Q: Is biotinoyl tripeptide-1 safe?
A: Yes — the safety profile is excellent. The GHK sequence is an endogenous collagen fragment processed normally by the body. Biotin is a water-soluble vitamin with no established toxicity. No significant adverse events have been reported in cosmetic use. The compound is well-tolerated across scalp types and does not share the systemic safety concerns of DHT-suppressing drugs like finasteride (sexual side effects) or the Wnt pathway cancer concern of PTD-DBM.
Related Compounds: How Biotinoyl Tripeptide-1 Compares
Biotinoyl tripeptide-1 is one of two ECM-anchoring peptides in the Hair & Follicle cluster — the other being acetyl tetrapeptide-3 (the active peptide component of Capixyl®). Both target follicle basement membrane reinforcement, but with different peptide sequences, different combination formulation contexts, and slightly different cellular emphasis. A detailed comparison of the two is covered in the acetyl tetrapeptide-3 article. The table below shows all compounds in the Hair & Follicle cluster.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Hair Growth Mechanism | Route / Application | Human Hair Evidence | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Biotinoyl Tripeptide-1 (Biotinylated GHK, Hair-Growth Targeting Copper Peptide) | Synthetic tripeptide conjugated to biotin (Biotin-Gly-His-Lys, biotin-modified GHK) | Hair follicle growth factor signaling (FGF / IGF-1 pathway proposed); copper-dependent metalloproteases | ~1–2 hours (topical) | Not FDA-approved (cosmetic / nutraceutical ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen extension; hair shaft strengthening (biotin carrier adds structural support) | Topical (shampoos, conditioners, scalp serums); Oral supplement (biotin component) | Limited human hair studies. Primarily marketed in hair-care cosmetics with anecdotal reports | Biotin-conjugated GHK targeting hair follicles specifically. Dual mechanism: copper peptide + biotin nutritional support |
| KGF / Palifermin (Keratinocyte Growth Factor) | Recombinant human FGF-7 (189-amino-acid heparin-binding growth factor) | FGF7R / HSPG (heparan sulfate proteoglycan); hair follicle epithelial growth | ~2–3 hours (injection); ~1 hour (topical — if penetrant) | FDA-approved (Kepivance for oral mucositis in hematologic malignancy patients) | Prohibited — S2 (Growth factor) | Tier 1 — Approved Drug (for mucositis indication; hair growth off-label) | Hair follicle keratinocyte proliferation (FGF-7 signaling); hair shaft diameter enlargement; hair cycle modulation (anagen phase extension proposed) | Subcutaneous or intradermal injection (research); Topical formulations under development | FDA-approved for oral mucositis (2004). Hair-growth studies limited; mostly preclinical or cosmetic-industry data | FGF-7 is gold-standard growth factor for hair follicle epithelium. Approved drug repurposed for hair (off-label interest) |
| Thymulin (Zinc-Thymulin) | Synthetic nonapeptide-zinc complex (Ac-SDAEPQ, zinc-dependent immuno-peptide from thymic epithelium) | Thymic T-cell development; hair follicle immune tolerance (proposed) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Thymic peptide hormone / growth factor) | Tier 4 — Preclinical Only | Hair follicle immune homeostasis (Th1/Th2 balance restoration); hair loss prevention via immune-mediated follicle protection (proposed) | Subcutaneous injection or topical (research formulations) | Zero human hair-loss studies published. Theoretical application based on immune function support | Thymic zinc peptide with general immune function. Proposed hair-loss mechanism via immune tolerance (alopecia areata context) |
| Substance P | Endogenous undecapeptide (11-amino-acid neuropeptide: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) | Tachykinin receptor 1 (NK1R) signaling; neuroinflammation and hair follicle support | ~1–2 minutes (blood serum); ~30 minutes (tissue microenvironment) | Not FDA-approved (endogenous neuropeptide, investigational) | Not WADA-listed (endogenous neuropeptide at physiologic levels) | Tier 4 — Preclinical Only | Neurogenic inflammation modulation (NK1R activation); hair follicle innervation support; anagen phase promotion (proposed in stress-induced alopecia contexts) | Subcutaneous or intradermal injection (research); Topical (experimental formulations) | Minimal human hair studies. Mostly rodent stress-alopecia models | Endogenous neuropeptide with rapid serum degradation. Proposed alopecia treatment via stress-pathway modulation |
| Copper Peptides: GHK-Cu & AHK-Cu | Two synthetic tripeptide-copper complexes (Gly-His-Lys + Cu²⁺ vs. Ala-His-Lys + Cu²⁺) | Collagen / Elastin synthesis; FGF signaling; hair follicle dermal papilla support | ~1–2 hours (topical) | Not FDA-approved (topical cosmetic ingredients widely used) | GHK-Cu: Prohibited — S0 (injectable); AHK-Cu: Not WADA-listed (topical) | GHK-Cu: Tier 5 — It’s Complicated | AHK-Cu: Tier 4 — Preclinical Only | Hair follicle collagen remodeling and stem cell support (GHK-Cu: broad effects; AHK-Cu: follicle-specific) | Topical only (shampoos, conditioners, serums; injectable GHK-Cu rare/unstandardized) | Topical: 30+ years cosmetic use (GHK-Cu more extensive); AHK-Cu: limited comparative studies | GHK-Cu: broader cosmetic/systemic research; AHK-Cu: more stable in formulations, follicle-targeted variant |
| IGF-1 (Insulin-Like Growth Factor 1, Recombinant) | Recombinant human 70-amino-acid growth factor peptide | IGF-1R (Type 1 insulin-like growth factor receptor); hair follicle stem cell proliferation | ~4–8 hours (injection); ~30 minutes (serum half-life) | Not FDA-approved for hair loss (approved for growth hormone deficiency pediatric indication only — Increlex) | Prohibited — S2 (Growth factor, IGF-1 analog) | Tier 2 — Clinical Trials (Phase II in hair loss) — historical | Hair follicle proliferation (IGF-1R signaling); anagen phase extension; hair shaft diameter increase (proposed) | Subcutaneous injection (research formulations); Topical (experimental — poor dermal penetration) | Phase II trials in alopecia (1990s—early 2000s); limited publication. Off-label interest in androgenetic alopecia | Recombinant growth factor with potent follicle effects in vitro/vivo. Systemic effects and cost limit practical use |
| Acetyl Tetrapeptide-3 (Hair-Growth Peptide) | Synthetic tetrapeptide (Ac-Glu-Glu-Lys-Ser, acetylated quadrapeptide) | Hair follicle growth factor signaling (proposed; exact mechanism unclear) | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen phase support; hair loss prevention (claims in cosmetic formulations) | Topical (shampoos, conditioners, scalp treatments) | Anecdotal cosmetic-industry reports only. No peer-reviewed human hair-loss studies | Short synthetic peptide with proprietary mechanism. Limited published evidence vs. marketing |
| PTD-DBM (Protein Transduction Domain — Double Binding Motif) | Synthetic peptide construct combining protein transduction domain (PTD) with collagen-binding domains (DBM) | Dermal collagen remodeling; hair follicle dermal papilla matrix support (proposed) | ~2–3 hours (topical/dermal penetration) | Not FDA-approved (research/cosmetic ingredient in development) | Not WADA-listed (topical research peptide) | Tier 4 — Preclinical Only | Hair follicle dermal matrix remodeling; collagen cross-linking enhancement (proposed) | Topical (serums, scalp treatments); potentially transdermal via PTD moiety | Limited studies. Primarily research-phase formulations | Combines transduction and collagen-binding domains for enhanced dermal penetration and matrix remodeling |
Summary and Key Takeaways
Biotinoyl tripeptide-1 targets an underaddressed mechanism in hair loss treatment — the progressive ECM detachment of follicles from the dermis — with a well-characterized in vitro mechanism, independent academic validation that laminin-332 deficit is real in AGA, and human combination data (Procapil®) showing measurable hair outcomes. The honest limitation is that biotinoyl tripeptide-1’s specific contribution to Procapil®’s effect cannot be isolated from the combination, and no standalone clinical trial exists. For the same reason that the argireline-plus-leuphasyl combination evidence doesn’t prove leuphasyl works alone, the Procapil® evidence doesn’t prove biotinoyl tripeptide-1 alone drives the observed hair outcomes. But the mechanism is real and the combination evidence is real — within the pilot data tier, that’s a defensible position.
- Biotinoyl tripeptide-1 (biotin conjugated to Gly-His-Lys) upregulates laminin-5 and collagen IV in follicle cells — reinforcing the basement membrane that anchors follicles to the dermis and is progressively degraded in AGA.
- Evidence tier: pilot data (combination). All human clinical data is from Sederma-sponsored Procapil® studies (biotinoyl tripeptide-1 + apigenin + oleanolic acid). Procapil® showed ~46% reduction in hair loss rate and improved anagen counts at 4 months in small industry-associated studies.
- Independent academic research confirms that laminin-332 expression is reduced in AGA follicles — validating the biological target independent of the compound’s manufacturer studies.
- Mechanism is completely distinct from and non-competing with PTD-DBM (Wnt activation), DHT inhibitors (finasteride), or minoxidil (vasodilation). Combining biotinoyl tripeptide-1 with these is mechanistically coherent.
- The biotin component is relevant in biotin-deficient individuals; marginal benefit for biotin-replete individuals from topical biotin delivery is not established.
- Safety profile: excellent. Endogenous GHK sequence + water-soluble vitamin. No significant adverse events in cosmetic use.
- Scalp microneedling is well-motivated — follicle outer root sheath target cells are at dermal depths accessible to 0.5–1.0 mm needle channels.
- WADA: not prohibited. Procapil® tradename: Croda/Sederma. Generic biotinoyl tripeptide-1 available from multiple suppliers.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References and Key Studies
- Sederma technical documentation: Procapil® active ingredient dossier. Croda International. Available at: croda.com/personal-care
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94. PMID 14996087 — ECM and follicle anchoring context in AGA treatment
- Rahmani W, et al. Hair follicle dermal cells support expansion of murine and human embryonic and induced pluripotent stem cells and promote their hair follicle differentiation. Stem Cells Dev. 2015. — follicle ECM biology
- Jahoda CA, et al. Induction of hair growth by implantation of cultured dermal papilla cells. Nature. 1984;311(5986):560–2. PMID 6482967 — foundational dermal papilla cell biology
- Garza LA, et al. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest. 2011;121(2):613–22. PMID 21206086 — AGA follicle structural compromise context
Further Reading
- Hair & Follicle Research Cluster — Peptidings.com
- PTD-DBM: Research Overview — Peptidings.com — Wnt activator; pairs with biotinoyl tripeptide-1 for multi-mechanism AGA coverage
- Acetyl Tetrapeptide-3: Research Overview — Peptidings.com — the other ECM-anchoring peptide in the cluster; comparison article covers both
- GHK-Cu: Research Overview — Peptidings.com — shares the GHK matrikine sequence; broader independent evidence base
- Peptide Microneedling & Stamping Guide — Peptidings.com — scalp microneedling protocols
- PubMed: Laminin-332 Hair Follicle Research
- Evidence Levels Explained — Peptidings.com
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing here should be interpreted as a recommendation to use any compound for hair loss treatment.
Biotinoyl tripeptide-1 is a cosmetic ingredient, not an FDA-approved drug. Published human data is available only for the Procapil® three-ingredient combination; biotinoyl tripeptide-1’s individual contribution cannot be isolated from that data. Procapil® is a registered trademark of Croda International (Sederma).
Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
← Previous
Next →
Resources & Further Research
Where to Go From Here
The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.
Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →
Telehealth Options
Happy Head
A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.
View Treatment Options →All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.